Hims & Hers Health (NYSE:HIMS) Insider Soleil Boughton Sells 25,111 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 25,111 shares of Hims & Hers Health stock in a transaction dated Wednesday, August 19th. The stock was sold at an average price of $27.55, for a total transaction of $691,808.05. Following the completion of the transaction, the insider owned 313,964 shares of the company’s stock, valued at $8,649,708.20. The trade was a 7.41% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Hims & Hers Health Stock Performance

Shares of HIMS stock opened at $31.95 on Friday. The firm’s 50 day moving average is $32.23 and its 200 day moving average is $26.09. The stock has a market capitalization of $7.45 billion, a P/E ratio of -50.71 and a beta of 2.40. Hims & Hers Health, Inc. has a 12 month low of $13.74 and a 12 month high of $65.30. The company has a current ratio of 0.93, a quick ratio of 0.87 and a debt-to-equity ratio of 4.21.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, August 10th. The company reported ($0.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.32). Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 6.51%. The business had revenue of $753.21 million during the quarter, compared to analysts’ expectations of $698.90 million. During the same quarter in the prior year, the firm posted $0.17 earnings per share. The firm’s quarterly revenue was up 38.2% on a year-over-year basis. On average, sell-side analysts anticipate that Hims & Hers Health, Inc. will post -0.05 earnings per share for the current year.

Key Stories Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: CEO Andrew Dudum defended Hims & Hers against the FTC’s allegations and said the company’s strategy could improve patient access and affordability. He also discussed a potential AI health coach that could support medication adherence, creating a possible long-term technology catalyst. Hims & Hers rejects privacy allegations
• Positive Sentiment: Some investors continue to view the recent margin weakness as an opportunity, citing Hims & Hers’ 38.2% year-over-year revenue growth and potential expansion into testosterone, peptides, branded GLP-1 treatments and international markets. However, execution and profitability remain important hurdles. Hims & Hers: Buying the Margin Dip
• Neutral Sentiment: Recent insider filings show sales by CFO Oluyemi Okupe, Deborah M. Autor and Soleil Boughton. The transactions were conducted under pre-arranged Rule 10b5-1 plans, and several sales were intended to cover tax obligations from vested equity awards. Because insiders retained substantial positions, the filings are a limited bearish signal rather than clear evidence of weakening confidence. SEC insider transaction filing
• Neutral Sentiment: Analyst sentiment remains mixed. The consensus rating is “Hold,” while Needham raised its price target to $42 and maintained a Buy rating. The split view reflects strong sales growth but concerns about losses, margins and the GLP-1 business strategy.
• Negative Sentiment: The FTC litigation and new investigations by Kaplan Fox and Berger Montague add potential legal costs, compliance requirements and reputational risk. The investigations focus on alleged sharing of private health data, deceptive billing and difficult subscription cancellations, keeping regulatory uncertainty over the stock. Kaplan Fox investigation
• Negative Sentiment: Hims & Hers’ latest quarter showed a larger-than-expected loss of $0.37 per share versus the $0.05 consensus estimate, despite revenue exceeding expectations. The earnings miss and negative profitability metrics could limit the stock’s upside until margins improve.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of HIMS. Resolute Advisors LLC bought a new position in shares of Hims & Hers Health in the second quarter worth approximately $322,000. QV Investors Inc. purchased a new stake in Hims & Hers Health in the second quarter valued at approximately $7,771,000. Kelly Lawrence W & Associates Inc. CA bought a new stake in Hims & Hers Health during the second quarter valued at approximately $11,520,000. Bank of New York Mellon Corp bought a new stake in Hims & Hers Health during the second quarter valued at approximately $46,220,000. Finally, Handelsbanken Fonder AB grew its stake in Hims & Hers Health by 4.0% in the 2nd quarter. Handelsbanken Fonder AB now owns 60,000 shares of the company’s stock worth $2,080,000 after buying an additional 2,300 shares in the last quarter. Hedge funds and other institutional investors own 63.52% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have recently weighed in on HIMS. JPMorgan Chase & Co. decreased their price target on Hims & Hers Health from $35.00 to $33.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 12th. UBS Group set a $23.00 price objective on shares of Hims & Hers Health in a research report on Friday, May 22nd. Morgan Stanley boosted their price objective on shares of Hims & Hers Health from $21.00 to $28.00 and gave the company an “equal weight” rating in a research note on Tuesday, August 11th. Zacks Research raised shares of Hims & Hers Health from a “strong sell” rating to a “hold” rating in a report on Monday, July 13th. Finally, Deutsche Bank Aktiengesellschaft increased their target price on shares of Hims & Hers Health from $25.00 to $26.00 and gave the stock a “hold” rating in a research note on Tuesday, August 11th. Four analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $32.43.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.